Adding Imfinzi (durvalumab) to standard first-line chemotherapy prolongs survival for adults newly diagnosed with inoperable malignant pleural mesothelioma, according to data from a Phase 2 clinical trial. This study is the first to show survival times exceeding 20 months in this patient population. A Phase 3 trial, called DREAM3R (NCT04334759), to confirm the combination’s superiority over chemotherapy alone is set to open in September. It will enroll patients at sites, yet to be announced, in the…
You must be logged in to read/download the full post.
The post Imfinzi Plus Chemo Aids Survival in Inoperable Pleural Mesothelioma, Phase 2 Data Show appeared first on BioNewsFeeds.